|
Demographic characteristics
|
Total (N = 293)
|
Male (n = 94)
|
Female (n = 199)
|
P value
|
|---|
|
Age(years)b
|
n (%)
|
n (%)
|
n (%)
| |
|
18–30
|
15 (5)
|
4 (4)
|
11 (6)
|
0.003
|
|
31–40
|
129 (44)
|
29 (31)
|
100 (50)
| |
|
41–50
|
106 (36)
|
39 (42)
|
67 (34)
| |
|
51–75
|
43 (15)
|
22 (23)
|
21 (10)
| |
|
Mean (sd)
|
42 (8)
|
44 (9)
|
40 (7)
| |
|
Educationa,b
|
|
Primary
|
23 (8)
|
12 (13)
|
11 (6)
|
0.012
|
|
Secondary
|
246 (84)
|
77 (82)
|
169 (85)
| |
|
Tertiary
|
24 (8)
|
5 (5)
|
19 (9)
| |
|
Employmentb
|
|
Employed
|
220 (75)
|
79 (84)
|
141 (71)
|
0.015
|
|
Not employed
|
73 (25)
|
15 (16)
|
58 (29)
| |
|
Marital statusb
|
|
Single
|
164 (56)
|
33 (35)
|
131 (66)
|
< 0.001
|
|
Married
|
129 (44)
|
61 (65)
|
68 (34)
| |
|
Behavioural characteristicb
|
|
Tobacco use
| | | | |
|
Non-smoker
|
277(95)
|
83 (88)
|
194 (97)
|
0.001
|
|
Smoker
|
16 (5)
|
11 (12)
|
5 (3)
| |
|
Alcohol useb
|
|
Yes
|
84 (29)
|
34 (36)
|
50 (25)
|
0.051
|
|
No
|
209 (71)
|
60 (64)
|
149 (75)
| |
|
Clinical characteristics
|
|
Treatment regimenc
|
|
DRV
|
144 (49)
|
49 (52)
|
95 (48)
|
0.483
|
|
LPV
|
149 (51)
|
45 (48)
|
107 (52)
| |
|
Number of adverse eventsd
|
|
0
|
92 (32)
|
37 (39)
|
55 (28)
|
0.061
|
|
1
|
85 (29)
|
30 (32)
|
55 (28)
| |
|
2
|
62 (21)
|
14 (15)
|
48 (24)
| |
|
3
|
54 (18)
|
13 (14)
|
41 (20)
| |
|
Severity of adverse eventsd
|
|
None
|
92 (31)
|
37 (39)
|
55 (28)
|
0.112
|
|
Mild
|
167 (57)
|
46 (49)
|
121 (61)
| |
|
Moderate–severe
|
34 (12)
|
11 (12)
|
23 (11)
| |
|
Pill burdend
|
|
0
|
41 (14)
|
15 (16)
|
26 (13)
|
0.087
|
|
1
|
29 (10)
|
14 (15)
|
15 (8)
| |
|
2
|
43 (15)
|
15 (16)
|
28 (14)
| |
|
3
|
37 (13)
|
11 (12)
|
26 (13)
| |
|
4+
|
143 (48)
|
39 (41)
|
104 (52)
| |
- N/n number, DRV darunavir, LPV lopinavir
- aFischer’s exact test
- Variables collected at bScreening visit, cEnrolment visit, dover the 48-week period (scheduled and unscheduled visits)
